Two new oral drugs for gonorrhea!
Dear All (wonkish … but worth it … get ready to follow the links!), Greetings in the new year! As a marvelous way to end
Dear All (wonkish … but worth it … get ready to follow the links!), Greetings in the new year! As a marvelous way to end
Dear All (and with thanks to Betsy Trainor for co-authoring), The idea of the STEDI values of an antibiotic (its fire extinguisher-like values) comes up
Dear All (and with thanks to Robert Skov for co-authoring this newsletter AND with a wonkish alert for this complicated topic for which a compelling
Dear All (with thanks to Kevin for leading on this newsletter and with a wonkish / long-read alert on this email … settle in for
Dear All, In a thoughtful companion to WHO’s preclinical and clinical pipeline reviews, we now have an instructive analysis of the global funding pipeline for
Dear All, I wrote in the 4 Oct 2025 newsletter about WHO’s updated reviews of antibacterial therapeutics and diagnostics. Team WHO have now released dashboard versions of
Dear All (and with thanks to Kevin Outterson for co-authoring this newsletter), Just out in CID is a paper in which FDA analyzes trends in
Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO
Dear All (and with thanks to Stephan Harbarth for co-authoring this newsletter), A new review by Ursula Theuretzbacher and colleagues from GARDP provides an opportunity
Dear All, On 26 Nov 2026, the Antimicrobial Resistance Surveillance & Research Initiative (AMRSRN) of the Indian Council on Medical Research (ICMR) released its report on